

CAPE FEAR VALLEY HEALTH SYSTEM

Policy – Procedure

Resident/Student Research
APPENDIX D
Non-Exempt Research

SUBMISSION CHECKLIST:

Prior to submitting request please ensure the following are included:

- _____ **Completed Resident/Student Project Approval Request form (attached)**
- _____ **Project Description including all elements identified in the “Non-Exempt Research Template” (attached)**
- _____ **Completed Research Review Summary Form (attached)**
- _____ **Patient consent (if applicable) including all elements identified in the “Informed Consent Template Checklist” (attached).**
- _____ **Documentation of current education for each investigator and protocol coordinator (One option for meeting this requirement is completion of Good Clinical Practice web-based training course (all modules) <https://gcp.nidatraining.org>).**

CAPE FEAR VALLEY HEALTH SYSTEM

Policy – Procedure

Resident/Student Research

APPENDIX D

Non-Exempt Research Template

GUIDELINES:

Projects that are thought to meet the definition of human subject research that do NOT qualify for exemption based on established exemption categories as identified by 45 CFR 46. 104(d) are to be submitted to the CFV IRB for an authoritative determination of their status by using the “Project Approval Request Form”. As a result of this review, the submission will be declared to be exempt from further IRB review, or determined to be a research study involving humans that is subject to further IRB review. **(NOTE: If project is determined to require full IRB review, you will be notified and additional paperwork/documentation may be required for full IRB review).**

A completed Research Review Summary should be submitted with the Project Approval Request Form. The Research Review Summary should include a detailed summary of the proposed research including the following elements:

Project Title

Project Aims

Project Methods

Data Collection Plan

Timeline

Evaluation Plan

Protected Health Information

Privacy, Data Storage & Confidentiality

Patient Consent (Is patient consent required? If no, indicate N/A. If yes, attach proposed patient consent prepared utilizing attached Consent Form Checklist to ensure all required elements are addressed).

Signature and Date of Submission:

CAPE FEAR VALLEY HEALTH SYSTEM
RESEARCH REVIEW SUMMARY

TITLE OF PROPOSAL/ACTIVITY: _____

PRINCIPAL INVESTIGATOR: _____ CO-INVESTIGATOR(S): _____

WHICH OF THE FOLLOWING ARE INVOLVED IN THIS STUDY:	YES	NO
Experimental devices, instruments, machines -----	___	___
Experimental procedures -----	___	___
Drugs under investigation -----	___	___
If yes, list name, manufacturer and drug study phase (I, II, III) _____		
Placebo(s) -----	___	___
Approved drugs for Non-FDA approved indications-----	___	___
Protocol approved at collaborating institution -----	___	___
If yes, name of institution: _____		
Patients as investigational subjects -----	___	___
Patients as control subjects -----	___	___
Pregnant subjects -----	___	___
Minors (less than 18 years) -----	___	___
Mentally incompetent subjects -----	___	___

DOES THIS RESEARCH PROPOSAL FALL INTO AN EXEMPT/NON-EXEMPT CATEGORY?

___ Exempt (see attached list of exemption categories) Exemption category _____
___ Non-exempt

IN THE JUDGMENT OF THE PRINCIPAL INVESTIGATOR, RESEARCH SUBJECTS WILL BE PLACED:

___ At no risk
___ At no more than minimal risk (NOTE: Minimal risk is defined as the risks of harm anticipated in the proposed research are not greater, considering probability and magnitude, than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
___ At more than minimal risk
Specify and quantitate each risk; describe steps taken to minimize recognizable risks: _____

The potential or anticipated benefits of this activity to the subjects or to mankind in general outweigh any recognized risks. This opinion is justified by the following reason(s): _____

POTENTIAL CONFLICT OF INTEREST

The following questions apply to any investigators or study staff involved with research, and/or their immediate family members (spouse, dependent children, others) and is inclusive of any business interest with which the investigator/study staff may be affiliated . Within the past 12 months or the next 12 months, have your or will you:

Receive any form of compensation from the Sponsor, including salary, consulting fees, honoraria, royalties, equipment, etc? ___ Yes ___ No
If so, does or will that compensation exceed \$10,000 ___ Yes ___ No

Have an ownership interest of any nature in the Sponsor or product under study, including equity, stock options, etc.? ___ Yes ___ No
If so, does or will that interest exceed \$10,000 in value? ___ Yes ___ No
If so, does that interest represent more than 5% ownership in the Sponsor? ___ Yes ___ No

Hold any position with the Sponsor, including officer, director, trustee consultant, member of advisory board, etc.? ___ Yes ___ No

Have an intellectual property interest on any technology or invention Used in this study, including patent rights, copyright, etc.? ___ Yes ___ No

If the answer is "yes" to any of the questions above, please include an explanation with this summary. As with any changes to the research itself, relationships or interests that develop later should be brought to the IRB's attention for further consideration.

WILL ANY SUBJECT INCUR ADDITIONAL PERSONAL EXPENSE (HOSPITAL CHARGES, ETC.)? AS THE RESULT OF PARTICIPATING IN THIS PROTOCOL? Yes No

If yes, please define: _____

WILL STUDIES BE DONE ON PATIENTS OF ATTENDING PHYSICIANS OTHER THAN INVESTIGATORS LISTED ON THE PROPOSAL? Yes No

If yes, please attach a statement signed by those attending physicians confirming they have consented to the involvement of their patients (if the patient consents).

HOW WILL CONFIDENTIALITY BE MAINTAINED? _____

HOW WILL INFORMED CONSENT BE OBTAINED (written/oral)? **DESCRIBE PROCESS** (by whom, one or more meetings, third party consent, etc.): _____

ATTACH A BRIEF SUMMARY OF PROPOSAL: This summary will be read by all committee members, including those who are "non-medical". It must be written using language they can understand. The summary should be succinct (100-400 words). Include: purpose of study; number, age and sex of subjects; duration; compensation; research methods; benefits; and risk. **DO NOT WRITE "SEE PROTOCOL"**. You must attach a well-written summary.

DOES THIS STUDY REQUIRE A CONTRACT WITH CFVHS? Yes No

If yes, has the contract been finalized Yes No

NOTE: If contract is required, IRB approval is contingent upon fully executed contract.

SIGNATURE, PRINCIPAL INVESTIGATOR

DATE

**CAPE FEAR VALLEY HEALTH SYSTEM
INSTITUTIONAL REVIEW BOARD
INFORMED CONSENT TEMPLATE CHECKLIST**

Does the first page of the consent contain the required “concise summary” Yes No

<u>YES</u>	<u>NO</u>	<u>N/A</u>	
_____	_____	_____	1. Can the entire consent form be understood by a lay person? (Try it out on your spouse, parents, or lay neighbors!)
_____	_____	_____	2. Does the consent form heading include the word research? <u>The word “research” must be in the consent form heading on each page.</u>
_____	_____	_____	3. Is there a statement indicating why the subject is being asked to take part in the study?
_____	_____	_____	4. Is there a statement to indicate the purpose and why the study is being done?
_____	_____	_____	5. Does the consent form indicate the study Phase and if so is there an explanation given to indicate what each phase entails? Ex. Phase 2, find out what effects (good and bad) _____ has on you and your type of cancer.
_____	_____	_____	6. Is there an indication or statement as to how many people will take part in the study? If approximate, then the consent form should state, about _____ people will take part in this study.
_____	_____	_____	7. Does the consent form clearly state what is involved in the study and for randomized studies is there an explanation of "randomization?"
_____	_____	_____	8. Is the length of the study participation clearly stated?
_____	_____	_____	9. Does the consent form identify the risks and benefits of study participation?
_____	_____	_____	10. Are other options/alternatives to study participation identified?
_____	_____	_____	11. Does the consent form indicate how confidentiality of participants is to be maintained?
_____	_____	_____	12. Are study costs clearly identified and compared to what would be the usual costs if the participant was not a part of the study
_____	_____	_____	13. Is there a statement to indicate that the participants insurance may or may not pay for some costs associated with the study and who is responsible for costs of travel, hospitalization, procedures, and tests?
_____	_____	_____	14. Does the consent form address participant rights regarding new information that may affect the participants health, wealth, or willingness to remain in the study?
_____	_____	_____	15. Is there a statement that study participation is voluntary and the participant may withdraw without jeopardizing continued care?
_____	_____	_____	16. Is there a statement indicating that the participants study records may be reviewed and or monitored by internal and external sources, i.e., National Cancer Institute, Food and Drug Administration?.
_____	_____	_____	17. Does the consent form indicate whom the participant is to call for problems or questions?
_____	_____	_____	18. Does the consent form identify where the participant can receive more information about their diagnosis and rights as a research participant?
_____	_____	_____	19. Is there a statement to indicate if the participant will or will not receive compensation for participation, if compensation is to be received are the amounts clearly stated and from whom the participant will receive the compensation and when ?

Checklist for Informed Consent

Page 2

<u>YES</u>	<u>NO</u>	<u>N/A</u>	
_____	_____	_____	20. Are issues of reproduction and the use of contraceptive devices addressed for both men and women?
_____	_____	_____	21. If the study involves a period of time (days—weeks), the consent form must indicate the need for contraceptive measures in sexually active women and men “If sexually active, I will take contraceptive measures for the duration of the research.” (or other similar language as determined appropriate by the IRB)
_____	_____	_____	22. Is there a statement to indicate continued availability of therapy after completion of the study?
_____	_____	_____	23. Does the consent form address under what circumstances the study participant's participation may be terminated?
			24. Does the consent form address the issue of hospital/research compensation?
			25. If applicable, does the consent form contain the following statement “A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required by US law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”

PLEASE NOTE THE FOLLOWING

All consent forms must list the principal investigator and any associates
Each page must have an appropriate title, consent form number, pagination (1 of 3 etc.), space for the participant's medical record number, and initials. The word research must be in the title of each consent form (all pages).

At the end of the consent form space must be provided for the date and signature of the participant/subject (parent and minors) or legal guardian, signature of individual who obtains consent, (should be investigator or co-investigator) and the person witnessing the signing of the consent form.

When a consent form has been modified all previous forms must be discarded.

NOTE: AFTER A CONSENT FORM HAS BEEN MODIFIED, ALL PREVIOUS FORMS MUST BE DISCARDED.